16 Centres Ordering in Europe, page-4

Brilliant news.... the last update we received on European sales there were 12 centres ordering CardioCel, now there are 16. An increase of 33%. As Lee Rodne has said in a previous ASX release, at these early stages its all about market penetration. This brings to 25 the total number of centres using CardioCel in The EU and The US. By the end of this calendar year its very feasible the company could be involved in 35 centres plus and by the end of next year over 100 centres should manufacturing conditions permit.

Why......

The snowball effect which begins with the Key Opinion Leaders at the top centres...... As more and more data is published, as more and more top surgeons speak in favour of CardioCel at conferences such as the EACTS which is taking place now then more and more surgeons will want to use the technology for its well established and proven competitive advantages. What we are seeing now is only the beginning and there are few, if any companies listed on the ASX which have the opportunity to grow revenues as rapidly as Admedus over the next 5 years.